Cagrilintide
$60.00
Cagrilintide is a long-acting amylin analogue peptide developed by Novo Nordisk to treat obesity and type 2 diabetes by mimicking natural amylin to reduce appetite and delay gastric emptying. Often studied in combination with semaglutide (CagriSema), it has shown significant, dose-dependent weight loss and is currently in Phase 3 trials.